Previscan /00789001/


Indications and Reactions:

Role Indications Reactions
Secondary
Drug Use For Unknown Indication 59.6%
Atrial Fibrillation 6.1%
Hypertension 5.3%
Pulmonary Embolism 4.8%
Cardiac Failure 3.4%
Product Used For Unknown Indication 3.0%
Bronchitis 2.4%
Epilepsy 2.0%
Atrial Flutter 1.2%
Deep Vein Thrombosis 1.2%
Depression 1.2%
Diabetes Mellitus 1.2%
Essential Hypertension 1.2%
Insomnia 1.2%
Rheumatoid Arthritis 1.2%
Thrombosis 1.2%
Oedema 1.0%
Type 2 Diabetes Mellitus 1.0%
Hypothyroidism 0.8%
Pain 0.8%
Renal Failure Acute 15.1%
Rectal Haemorrhage 8.1%
Thrombocytopenia 8.1%
International Normalised Ratio Increased 7.0%
Vomiting 5.8%
Weight Decreased 5.8%
Fall 4.7%
Prothrombin Level Decreased 4.7%
Shock Haemorrhagic 4.7%
Subdural Haematoma 4.7%
Toxic Skin Eruption 4.7%
Interstitial Lung Disease 3.5%
Muscle Haemorrhage 3.5%
Rash Erythematous 3.5%
Renal Failure 3.5%
Sinoatrial Block 3.5%
Drug Interaction 2.3%
Eczema 2.3%
Haematoma 2.3%
Jaundice 2.3%
Concomitant
Drug Use For Unknown Indication 62.3%
Product Used For Unknown Indication 10.5%
Atrial Fibrillation 3.7%
Hypertension 3.7%
Type 2 Diabetes Mellitus 2.2%
Arrhythmia 2.1%
Prophylaxis 1.9%
Breast Cancer 1.8%
Multiple Myeloma 1.6%
Rheumatoid Arthritis 1.5%
Cardiac Failure 1.3%
B-cell Lymphoma 0.9%
Endocarditis Staphylococcal 0.9%
Nephrotic Syndrome 0.9%
Osteitis 0.9%
Pain 0.9%
Abscess 0.7%
Gout 0.7%
Depression 0.6%
Hiv Infection Cdc Category C3 0.6%
Renal Failure Acute 35.9%
Thrombocytopenia 9.8%
Vomiting 7.6%
Hyponatraemia 4.3%
Neutropenia 4.3%
Somnolence 4.3%
Renal Failure 3.3%
Septic Shock 3.3%
Weight Increased 3.3%
Cardiac Failure 2.2%
Chronic Lymphocytic Leukaemia 2.2%
Dermatitis Exfoliative 2.2%
Head Discomfort 2.2%
International Normalised Ratio Increased 2.2%
Malaise 2.2%
Nausea 2.2%
Orthostatic Hypotension 2.2%
Pancreatitis Acute 2.2%
Pancytopenia 2.2%
Pruritus 2.2%

Drug Data